In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. 

To learn more about the topics in this episode: 
Fierce Medtech's Fierce 15 of 2023

In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/special-reports/fierce-medtechs-fierce-15-2023" data-cke-saved-href="https://www.fiercebiotech.com/special-reports/fierce-medtechs-fierce-15-2023">Fierce Medtech's Fierce 15 of 2023</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Fierce Medtech's Fierce 15

This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.

Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the numerous high-value deals in 2023, which companies are primed to make major moves this year, and whether the trend of acquiring ADCs and obesity treatments will continue. 

To learn more about the topics in this episode: 
The top 10 biopharma M&A deals of 2023
2024 forecast: M&A saw an uptick in 2023. Analysts expect the trend to continue
For biopharma M&A, the best returns come from small deals: analysts

This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.
Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the numerous high-value deals in 2023, which companies are primed to make major moves this year, and whether the trend of acquiring ADCs and obesity treatments will continue. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023" data-cke-saved-href="https://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023">The top 10 biopharma M&amp;A deals of 2023</a></li>
<li><a href="https://www.fiercepharma.com/pharma/2024-forecast-ma-saw-uptick-2023-expect-trend-continue" data-cke-saved-href="https://www.fiercepharma.com/pharma/2024-forecast-ma-saw-uptick-2023-expect-trend-continue">2024 forecast: M&amp;A saw an uptick in 2023. Analysts expect the trend to continue</a></li>
<li><a href="https://www.fiercepharma.com/pharma/analysts-prescription-big-pharma-take-ma-small-doses" data-cke-saved-href="https://www.fiercepharma.com/pharma/analysts-prescription-big-pharma-take-ma-small-doses">For biopharma M&amp;A, the best returns come from small deals: analysts</a></li>
</ul>

A closer look at 2023's top biopharma deals and what lies ahead

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.  

This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.  

To learn more about the topics in this episode:  
The top 20 pharma companies by 2023 revenue
The top 20 pharma companies by 2022 revenue

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.  
This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.  
To learn more about the topics in this episode:  
<ul>
<li><a href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue" data-cke-saved-href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue">The top 20 pharma companies by 2023 revenue</a></li>
<li><a href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2022-revenue" data-cke-saved-href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2022-revenue">The top 20 pharma companies by 2022 revenue</a></li>
</ul>

A look at pharma revenue rankings

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce.

This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our biannual Drug Names tournament.

The editors discuss what makes a company or drug name tick, what to steer clear of, and how the entire competition played out. 

To learn more about the topics in this episode: 
#FierceMadness: AstraZeneca and Ionis cruise to victory as Wainua trounces Lilly's Mounjaro for the tournament win
#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce.
This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our biannual Drug Names tournament.
The editors discuss what makes a company or drug name tick, what to steer clear of, and how the entire competition played out. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/marketing/fierce-madness-back-get-voting-2024-drug-name-tournament" data-cke-saved-href="https://www.fiercepharma.com/marketing/fierce-madness-back-get-voting-2024-drug-name-tournament">#FierceMadness: AstraZeneca and Ionis cruise to victory as Wainua trounces Lilly's Mounjaro for the tournament win</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-madness-best-biotech-name-championship-2024" data-cke-saved-href="https://www.fiercebiotech.com/biotech/fierce-madness-best-biotech-name-championship-2024">#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED</a></li>
</ul>

Fierce Medtech's Fierce 15

The Top Line

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips